Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

IPAD Trial Ended

2024-513124-41-00 Primary antibody deficiency: - Unclassified antibody de 5 2024-07-12
An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered… Ended

2023-509002-30-00 Chronic obstructive pulmonary disease 3 2024-06-25
Effect of SAR445611 on inflammatory responses following LPS challenge study in healthy participants Ended

2024-511618-19-00 Immune system diseases 3 2024-06-24
A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and … Ended

2023-503917-31-00 Inflammatory disease 1 2024-06-24
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-77242113 in Adult Participants Ended

2023-510161-97-00 Renal Impairment 3 2024-06-19
A Phase 1b, Open-Label, Single-Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of ANX15… Ended

2023-507017-10-00 Primary Cold Agglutinin Disease (CAD) 3 2024-06-17
A Phase I, open-label, randomized, two period, cross-over study in healthy subjects to assess the bioavailability of different formulations … Ended

2024-511196-15-00 Hereditary angioedema (HAE) 3 2024-06-13
RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHAR… Ended

2023-510247-38-00 Rheumatoid arthritis 3 2024-06-07
Multiple Ascending Doses of BMS-986326 in Participants with Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic… Ended

2022-503009-39-00 Subacute Cutaneous Lupus Erythematosus 3 2024-06-04
A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet… Ended

2024-512220-11-00 Inflammatory Conditions 3 2024-05-23
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-C3 in Adult Healthy V… Ended

2023-506690-36-00 complement-mediated renal disease 9 2024-05-06
MK-2420 SAD Study Ended

2024-511297-73-00 Rheumatoid arthritis 1 2024-05-03
A Study of the Efficacy, Safety, and Tolerability of KAN-101 in Participants With Celiac Disease Ended

2023-507240-37-00 celiac disease 4 2024-04-30
Rapid pain control in Ixekizumab targeted axial spondyloarthritis Ended

2023-508976-12-00 axial spondyloarthritis 6 2024-04-29
A Study to Learn About the Study Medicine Called PF-07054894 in People of Japanese Origin Ended

2023-509339-17-00 Inflammatory bowel disease 3 2024-04-15
Proof-of-concept study evaluating subcutaneous amlitelimab in adult participants with moderate to severe hidradenitis suppurativa. Ended

2023-505803-22-00 Hidradenitis 4 2024-04-15
A placebo-controlled safety and tolerability study of intravenous (IV) and subcutaneous (SC) AZD1163 in healthy volunteers Ended

2023-509574-34-00 Rheumatoid Arthritis 1 2024-04-10
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to… Ended

2023-504564-42-00 Moderate to Severe Rheumatoid Arthritis 4 2024-04-08
A phase IIb study to Assess the Efficacy and Safety of SCD-044 in the Treatment of Moderate to Severe Plaque Psoriasis Ended

2023-506477-35-00 moderate to severe plaque psoriasis 4 2024-04-02
Investigating the safety, feasibility, and optimal dose of Adalimumab-680LT in IBD – GUIDE study Ended

2023-508391-11-00 Inflammatory Bowel Disease (IBD) 7 2024-03-21
A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to he… Ended

2023-509030-19-00 Plaque Psoriasis 3 2024-03-18
A clinical study of MK-6194 for the treatment of Systemic Lupus Erythematosus (SLE) (MK-6194-006) Ended

2023-505520-61-00 Systemic Lupus Erythematosus 10 2024-03-11
A six-way relative bioavailability study comparing 10, 30, 40 and 50 mg leniolisib film coated tablets and 30 mg film coated granules with 7… Ended

2023-508880-61-00 Activated Phosphoinositide 3-Kinase Delta Syndrome 3 2024-03-06
A Phase 1b/2a, Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Pa… Ended

2023-507534-24-00 Chronic Inducible Urticaria 9 2024-03-06